Menarini Group (Italy)

Recent papers from Menarini Group (Italy)

1. Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitorFuture Oncology · 2026
2. ESMO and ASCO Consensus on Good Clinical Practice Guideline E6(R3): A Step Forward Towards Streamlining Clinical ResearchESMO Open · 2026
3. Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world settingESMO Open · 2026
4. Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATEClinical Cancer Research · 2026
5. Probiotic Yeasts and Bacteria: A Complementary Approach to Gut HealthMicroorganisms · 2026
6. Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysisFrontiers in Oncology · 2026
7. Skin Acceptability of a Topical Cream Containing Zinc Oxide, Zinc Gluconate, Taurine and Panthenol in Females With Urinary IncontinenceJournal of Cosmetic Dermatology · 2026
8. Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase IILeukemia · 2026
9. Efficacy and Safety of Nebivolol as Compared to Placebo or Other Beta-Blockers in Hypertensive Patients: A Systematic Review and Network Meta-AnalysisJournal of Hypertension · 2026
10. Serum Uric Acid Hyperproduction as a Potentially Distinct Phenotype in Gout Patients on Chronic Treatment With Xanthine Oxydase Inhibitor: A Post Hoc AnalysisJournal of Hypertension · 2026
11. ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from ER+/HER2− breast cancer.Journal of Clinical Oncology · 2026
12. Elacestrant in combination with capivasertib in patients with ER+/HER2− advanced breast cancer: Update from ELEVATE, a phase 1b/2, open-label, umbrella study.Journal of Clinical Oncology · 2026
13. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE studyEuropean Heart Journal · 2010
14. Abstract CT262: Elacestrant (Ela) in combination with everolimus (Eve) or abemaciclib (Abema) in patients with ER+/HER2- locally advanced or metastatic breast cancer mBC: phase 2 results from ELEVATE, an open-label, umbrella studyCancer Research · 2026
15. Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide‐refractory multiple myeloma: Subgroup analysis of the BOSTON trialBritish Journal of Haematology · 2026
16. Characterisation of Antisense Oligonucleotides by Ion‐Pair Reversed‐Phase UHPLC‐HRMS: Method development using Design of ExperimentsJournal of Mass Spectrometry · 2026
17. Physician attitudes toward natural syrup formulations for cough and sore throat: a multinational cross-sectional survey of 398 healthcare professionals across 13 countriesFrontiers in Pharmacology · 2026
18. Effect of aclidinium bromide therapy on quality of life and symptoms of patients with chronic obstructive pulmonary disease: pooled analysis results of the Greek and Austrian ON-AIR real-world observational studiesBMC Pulmonary Medicine · 2026
19. Abstract PS3-08-06: Elegant: elacestrant versus standard endocrine therapy (ET) in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer (eBC) with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 studyClinical Cancer Research · 2026
20. Abstract RF7-01: Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella studyClinical Cancer Research · 2026